Anti-Müllerian Hormone Is a Marker of Gonadotoxicity in Pre- and Postpubertal Girls Treated for Cancer: A Prospective Study

Brougham, Mark; Crofton, Patricia M.; Johnson, Emma; Evans, Nancy; Anderson, Richard A.; Wallace, W. Hamish B.

doi:10.1210/jc.2011-3180

Cited by 185 publications

(128 citation statements)

References 36 publications

(44 reference statements)

Supporting

Mentioning

108

Contrasting

Unclassified

Order By: Relevance

“…In the pivotal study by Anderson et al [41], AMH serum levels rapidly and markedly fell after the first cycles of CT and during the treatment, becoming undetectable in many patients. AMH serum levels may even increase again over time, but return to pre-CT levels appeared unlikely [37,[47][48][49]. In large casecontrol studies, BC survivors who underwent CT had lower AMH serum levels than age-matched controls [45,46].…”

Section: Discussionmentioning

confidence: 99%

Predicting Ovarian Activity in Women Affected by Early Breast Cancer: A Meta-Analysis-Based Nomogram

Barnabei¹,

Strigari

Marchetti

et al. 2015

The Oncologist

View full text Add to dashboard Cite

Background. The assessment of ovarian reserve in premenopausal women requiring anticancer gonadotoxic therapy can help clinicians address some challenging issues, including the probability of future pregnancies after the end of treatment. Anti-Müllerian hormone (AMH) and age can reliably estimate ovarian reserve. A limited number of studies have evaluated AMH and age as predictors of residual ovarian reserve following cytotoxic chemotherapy in breast cancer patients. Materials and Methods. To conduct a meta-analysis of published data on this topic, we searched the medical literature using the key MeSH terms "amenorrhea/chemically induced," "ovarian reserve," "anti-Mullerian hormone/blood," and "breast neoplasms/drug therapy." Preferred Reporting Items for Systematic Reviews and Meta-Analyses statements guided the search strategy. U.K. National Health Service guidelines were used in abstracting data and assessing data quality and validity. Area under the receiver operating characteristic curve (ROC/AUC)

show abstract

Section: Discussionmentioning

confidence: 99%

Predicting Ovarian Activity in Women Affected by Early Breast Cancer: A Meta-Analysis-Based Nomogram

Barnabei¹,

Strigari

Marchetti

et al. 2015

The Oncologist

View full text Add to dashboard Cite

show abstract

“…The authors demonstrated that AMH was detectable in girls of all ages but decreased progressively during chemotherapy in both preand post-pubertal girls, eventually becoming undetectable in 50% of patients. AMH levels showed no recovery in the high-risk group, while there was a recovery in the low/medium risk group after the completion of chemotherapy (Brougham et al 2012). Interestingly, authors observed that AMH, due to the physiological quiescence of the hypothalamic-pituitary-gonadal axis at this age, was the only reliable biomarker for ovarian damage evaluation in prepubertal children (Brougham et al 2012).…”

Section: Amh and Chemo-induced Gonadal Damage In Cancer Patientsmentioning

confidence: 99%

“…Furthermore, they showed that high pretreatment AMH levels were predictive of higher AMH levels during recovery of ovarian function after chemotherapy (Rosendahl et al 2010). Brougham et al (2012) prospectively evaluated AMH levels in children as a marker of ovarian reserve during cancer treatment. A total of 22 patients with a median age of 4.4 years were enrolled before initiation of cancer treatment.…”

Section: Amh and Chemo-induced Gonadal Damage In Cancer Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Anti-Müllerian hormone: determination of ovarian reserve in early breast cancer patients

Bozza¹,

Puglisi²,

Lambertini³

et al. 2013

Endocrine-Related Cancer

View full text Add to dashboard Cite

Breast cancer is the most common invasive cancer in women of reproductive age. In young women, chemotherapy may induce amenorrhea: it is still uncertain how to assess menopausal status in these patients despite the importance of its definition for choosing appropriate endocrine treatment. In the development of sensitive biomarkers for fertility and ovarian reserve, anti-Mü llerian hormone (AMH) is considered a promising marker of ovarian reserve. The clearest data regarding a clinical use of AMH are related to the measurement of the ovarian pool in women who undergo IVF: the available data, also in breast cancer patients, seem to suggest that AMH measurement, before gonadotropin administration, can be a useful marker for the prediction of women at risk for poor-response or no response to ovarian stimulation. The utility of AMH as a potential marker of chemotherapy-induced ovarian follicular depletion and an early plasma marker of chemotherapy-induced gonadal damage has been evaluated both in young women after treatment for cancer in childhood and in young survivors of hematological malignancies and solid tumors. Several studies have demonstrated a potential utility of AMH, inhibin, or follicle-stimulating factor as biomarkers predicting infertility risk in breast cancer patients, but the studies conducted so far are not conclusive. Further studies are needed in order to define the regimen-specific action of chemotherapy on AMH levels, the percentage of post-treatment recovery of plasma levels of the hormone, and the relationship between menopausal status and AMH.

show abstract

“…Antimül-lerian hormone is detectable at all ages and, unlike fsh, is stable throughout the menstrual cycle; it can therefore be assessed at the time of presentation. In combination with the patient's age, amh can help to assess future fertility by quantifying the short-term chemotoxic effects on ovarian reserve 59 , providing an estimated age of menopause 60,61 and assessing the patient's susceptibility to the gonadotoxic effects of chemotherapy 62,63 .…”

Section: Assessment Of the Young Cancer Patientmentioning

confidence: 99%

Fertility Preservation in Reproductive-Age Women Facing Gonadotoxic Treatments

et al. 2015

View full text Add to dashboard Cite

show abstract

Anti-Müllerian Hormone Is a Marker of Gonadotoxicity in Pre- and Postpubertal Girls Treated for Cancer: A Prospective Study

Cited by 185 publications

References 36 publications

Predicting Ovarian Activity in Women Affected by Early Breast Cancer: A Meta-Analysis-Based Nomogram

Predicting Ovarian Activity in Women Affected by Early Breast Cancer: A Meta-Analysis-Based Nomogram

Anti-Müllerian hormone: determination of ovarian reserve in early breast cancer patients

Fertility Preservation in Reproductive-Age Women Facing Gonadotoxic Treatments

Contact Info

Product

Resources

About